GE and Catholic Health enter $500m alliance to expand diagnostics access
GE HealthCare and Catholic Health have signed a ten-year strategic alliance valued at around $500m, aimed at expanding access to…
All articles by Salong Debbarma
Salong Debbarma
-
-
First patients dosed in Grifols Phase III immunoglobulin trials
Grifols has dosed the first patients in two separate Phase III trials designed to support the US label expansion of…
-
JCVI issues recommendation on adolescent MenB vaccination in UK
The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine programme with the 4CMenB vaccine for adolescents.…
-
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Kairos Pharma has reported interim safety results from its ongoing Phase I clinical trial of ENV-105 (carotuximab), along with AstraZeneca's…
-
Smith+Nephew unveils Lynx Coblation Laryngeal Wand for laryngology
Smith+Nephew has commercially launched its Lynx Coblation Laryngeal Wand, a device developed for ear, nose and throat (ENT) surgeons carrying…
-
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration (NMPA) for their investigational new drug (IND)…
-
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
Sound Pharmaceuticals has concluded subject enrolment for its second Phase III clinical trial assessing SPI-1005 in adults with probable or…
-
Neuraptive secures exclusive licence from Washington University for nerve device
Neuraptive Therapeutics has secured an exclusive licence from Washington University in St Louis for a bioresorbable wireless electronic stimulation device…
-
Innovent licenses IBI355 rights to Spero for up to $1.1bn
Innovent Biologics has agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to…
-
Claria Medical secures FDA De Novo classification for hysterectomy device
Claria Medical has secured De Novo classification and marketing authorisation from the US Food and Drug Administration (FDA) for its…